Dear non-clinical colleagues, following our previous discussion on the reproductive and developmental toxicity of traditional drugs, this time we will briefly discuss how to evaluate “special drugs” — “Which components of ADCs, such as antibodies, linkers, or payloads, need to be assessed for reproductive toxicity?” “Will gene therapy viral vectors integrate into germ cells, and how can we detect this?” “After CAR-T cells are infused, will they migrate to the testes/ovaries, leading to offspring issues?”